PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
PaxMedica (OTC PINK:PXMD) has received its first patent allowance in China for a novel intranasal formulation of suramin to treat autism spectrum disorder and other neurological conditions. The patent (Application No: 2020800553323) covers claims for treating neurological disorders using intranasal delivery of suramin, representing a significant departure from its traditional infusion dosing method.
This marks the first time in over 100 years that intellectual property protection has been granted for any form of suramin. The company has similar patent applications pending in multiple jurisdictions, including the United States, as it continues to expand its intellectual property portfolio.
PaxMedica (OTC PINK:PXMD) ha ricevuto la sua prima concessione di brevetto in Cina per una nuova formulazione intranasale di suramina per il trattamento dei disturbi dello spettro autistico e di altre condizioni neurologiche. Il brevetto (Numero di domanda: 2020800553323) copre le rivendicazioni per il trattamento dei disturbi neurologici utilizzando la somministrazione intranasale di suramina, rappresentando un significativo allontanamento dal tradizionale metodo di infusione.
Questo segna la prima volta in oltre 100 anni che è stata concessa una protezione della proprietà intellettuale per qualsiasi forma di suramina. L'azienda ha simili domande di brevetto in attesa in diverse giurisdizioni, compresi gli Stati Uniti, mentre continua ad espandere il suo portafoglio di proprietà intellettuale.
PaxMedica (OTC PINK:PXMD) ha recibido su primera concesión de patente en China para una nueva formulación intranasal de suramina para tratar el trastorno del espectro autista y otras condiciones neurológicas. La patente (Número de solicitud: 2020800553323) cubre las reclamaciones para el tratamiento de trastornos neurológicos utilizando la administración intranasal de suramina, representando un cambio significativo con respecto a su método tradicional de dosificación por infusión.
Esto marca la primera vez en más de 100 años que se concede protección de propiedad intelectual para cualquier forma de suramina. La empresa tiene solicitudes de patente similares pendientes en múltiples jurisdicciones, incluyendo Estados Unidos, mientras continúa expandiendo su cartera de propiedad intelectual.
PaxMedica (OTC PINK:PXMD)는 자폐 스펙트럼 장애 및 기타 신경학적 질환 치료를 위한 새로운 비강 제형의 수라민에 대해 중국에서 첫 특허 허가를 받았습니다. 특허 (신청 번호: 2020800553323)는 수라민의 비강 투여를 통해 신경학적 질환을 치료하는 것에 대한 청구 항목을 포함하고 있으며, 이는 전통적인 주입 방식에서 상당한 이탈을 나타냅니다.
이는 100년 넘게 수라민의 어떤 형태에 대해서도 지식 재산 보호가 부여된 첫 번째 사례입니다. 이 회사는 미국을 포함한 여러 관할권에서 유사한 특허 신청을 대기 중이며, 지식 재산 포트폴리오를 계속 확장해 나가고 있습니다.
PaxMedica (OTC PINK:PXMD) a reçu son premier brevet en Chine pour une nouvelle formulation intranasale de suramine destinée à traiter le trouble du spectre autistique et d'autres conditions neurologiques. Le brevet (Numéro de demande : 2020800553323) couvre les revendications relatives au traitement des troubles neurologiques par administration intranasale de suramine, représentant un changement significatif par rapport à sa méthode traditionnelle d'administration par perfusion.
C'est la première fois en plus de 100 ans qu'une protection de propriété intellectuelle est accordée pour toute forme de suramine. L'entreprise a des demandes de brevet similaires en attente dans plusieurs juridictions, y compris les États-Unis, tout en continuant à élargir son portefeuille de propriété intellectuelle.
PaxMedica (OTC PINK:PXMD) hat in China sein erstes Patent für eine neuartige intranasale Formulierung von Suramin zur Behandlung von Autismus-Spektrum-Störungen und anderen neurologischen Erkrankungen erhalten. Das Patent (Antragsnummer: 2020800553323) umfasst Ansprüche zur Behandlung neurologischer Störungen mit intranasaler Verabreichung von Suramin, was einen erheblichen Wandel von der traditionellen Infusionsmethode darstellt.
Dies ist das erste Mal seit über 100 Jahren, dass geistiges Eigentum für irgendeine Form von Suramin gewährt wurde. Das Unternehmen hat ähnliche Patentanträge in mehreren Jurisdiktionen, einschließlich der Vereinigten Staaten, ausstehend, während es weiterhin sein geistiges Eigentumsportfolio erweitert.
- First patent allowance received in China for intranasal suramin formulation
- Novel delivery method (intranasal) potentially improving upon traditional infusion dosing
- First intellectual property protection for suramin in over 100 years
- Multiple patent applications pending in other jurisdictions
- Patent approval to China market only
- Pending applications in other key markets still face uncertainty
BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.
Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been approved, since it was first used in humans over 100 years ago. This patent covers claims for treating neurological disorders, such as autism, using a novel formulation of suramin for intranasal delivery, rather than its current infusion dosing. Similar patent applications are filed in multiple, sovereign jurisdictions, and we will continue to pursue claims in other territories, including the United States."
About PaxMedica
PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders. Our comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), as well as other critical areas within the neurology field. Additionally, we intend to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense.
We are dedicated to the continuous development and evaluation of our pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of our efforts, particularly focused on innovative ASD treatment solutions. Our ongoing research initiatives not only prioritize the needs of ASD patients, but also extend to exploring potential therapeutic applications for related conditions. To learn more about our transformative work, please visit www.paxmedica.com.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.paxmedica.com/email-alerts and by following PaxMedica on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements reflect our current view about future events. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. These forward-looking statements include our anticipated clinical program, the timing and success of our anticipated data announcements, pre-clinical and clinical trials and regulatory filings, and distribution and demand for our product candidates. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of the Company's product development and clinical trials, risk of insufficient capital resources, cash funding and cash burn, regulatory approvals and risks associated with intellectual property and infringement claims. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company's "Risk Factors" section and other sections in its most recent Annual Report on Form 10-K, and subsequent quarterly and other filings with the U.S. Securities and Exchange Commission.
Contacts
PaxMedica, Inc.
101 Arch St., 8th Floor
Boston, MA 02110
www.paxmedica.com
Media Contact
media@paxmedica.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
ir@paxmedica.com
www.paxmedica.com/investors
SOURCE: PaxMedica, Inc.
View the original press release on accesswire.com
FAQ
What patent did PXMD receive for its suramin formulation in January 2024?
How is PXMD's new suramin delivery method different from traditional methods?
Where else has PXMD filed patent applications for its suramin formulation?
What conditions will PXMD's patented suramin formulation treat?
